Sandra Sanabria Bohórquez

Author

Also Known As

S M Sanabria Bohorquez, S Sanabria-Bohórquez, S. Sanabria Bohorquez, S. Sanabria-Bohorquez, S. Sanabria‐Bohorquez, S.M. Sanabria Bohórquez, SM Sanabria-Bohórquez, Sandra M Sanabria-Bohorquez, Sandra M Sanabria-Bohórquez, Sandra M. Sanabria Bohorquez

119

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

United States Military Academy KU Leuven Merck & Co., Inc., Rahway, NJ, USA (United States)MSD (Belgium)UCLouvain

About

Sandra Sanabria Bohórquez is an author at United States Military Academy specializing in medicine, neuroscience, and social sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	1.6K
2	Social Sciences	11	12	451
3	Health Sciences	6	6	1.2K
4	Engineering	2	2	48
5	Arts	1	1	72

Sandra Sanabria Bohórquez

Publications

Citations

H-Index

Page 1

	Year	Citations
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub–de Hooge, Nature Medicine Oncologic ImagingPd-l1 BlockadeMedicineImmune Checkpoint InhibitorTherapeutic Imaging	2018	702
[<sup>18</sup>F]MK-9470, a positron emission tomography (PET) tracer for<i>in vivo</i>human PET brain imaging of the cannabinoid-1 receptor H. Donald Burns, Koen Van Laere, Sandra Sanabria Bohórquez, Proceedings of the National Academy of Sciences	2007	311
The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake Carol Addy, Hamish Wright, Koen Van Laere, Cell Metabolism ObesityMetabolic SyndromeCaloric RestrictionEnergy MetabolismEnergy Homeostasis	2008	200
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease Susanne Ostrowitzki, Tobias Bittner, Kaycee M. Sink, JAMA Neurology	2022	197
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults Ngozi Erondu, Ira Gantz, Bret J. Musser, Cell Metabolism ObesityMetabolic SyndromeMeaningful Weight LossPhysiologyObesity Management	2006	181
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease Edmond Teng, Paul T. Manser, Karen Pickthorn, JAMA Neurology	2022	173
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors Cristina Saura, Desamparados Roda, Susana Roselló, Cancer Discovery	2016	167
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Cancer Discovery	2017	159
Occipital Activation by Pattern Recognition in the Early Blind Using Auditory Substitution for Vision Patricia Arno, Anne De Volder, Annick Vanlierde, NeuroImage Early VisionCognitive ScienceOphthalmologyPattern RecognitionNeurolinguistics	2001	150
The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort Pierre N. Tariot, Francisco Lopera, Jessica B. Langbaum, Alzheimer s & Dementia Translational Research & Clinical Interventions	2018	129

Page 1